Chris Eades

Dr. Chris Eades

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
CEChris Eades
Chris Eades
ABAhmed Rafezzan Bin Ahmed Bakri
Ahmed Rafezzan Bin Ahmed Bakri
JLJeffrey C. Y. Lau
Jeffrey C. Y. Lau
CMCaroline B. Moore
Caroline B. Moore
LNLilyann Novak-Frazer
Lilyann Novak-Frazer
Riina Rautemaa-RichardsonRiina Rautemaa-Richardson
Riina Rautemaa-Richardson
Invasive candidiasis, including bloodstream infection (candidemia), encompasses the most severe forms of Candida infection. Several species-specific and non-specific serological assays are commercially available to aid in diagnosis. This study compared the performance of five such biomarker assays. Serum samples from 14 patients with proven or probable invasive candidiasis, and from 10 control patients, were included in the analysis. A total of 50 serum samples were tested using C. albicans germ tube antibody (CAGTA) assay (Vircell), C. albicans IgM, C. albicans IgG and Candida mannan assays (Dynamiker Biotechnology). Among these samples, the β-1-3-D-glucan (BDG) assay (Fungitell), a laboratory standard for the diagnosis of invasive candidiasis, was positive in 20 (40%), intermediate in five (10%) and negative in 25 (50%). In cases of proven or probable candidemia, the sensitivity and specificity of the BDG assay was 86% and 80%, respectively; the Candida mannan assay, 14% and 86%; the CAGTA test, 57% and 60%; the C. albicans IgM assay, 71% and 60%; and C. albicans IgG assay 29% and 90%. In 4/8 (50%) cases with multiple serum samples, C. albicans IgM was positive sooner than BDG. Thus, when used as a rule-out test for invasive candidiasis, our data suggest that the C. albicans IgM assay may assist antifungal stewardship (over serum BDG).

15 February 2018 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
PDF file
CEChris Eades
Chris Eades
DADarius Armstrong-James
Darius Armstrong-James
JPJimstan Periselneris
Jimstan Periselneris
AJAndrew Jones
Andrew Jones
NSNicholas Simmonds
Nicholas Simmonds
ASAnand Shah
Anand Shah

6 October 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Mireille van der TorreMireille van der Torre
Mireille van der Torre
CWCheryl Whitby
Cheryl Whitby
CEChris Eades
Chris Eades
CMCaroline B. Moore
Caroline B. Moore
LFLily Novak Frazer
Lily Novak Frazer
Riina Rautemaa-RichardsonRiina Rautemaa-Richardson
Riina Rautemaa-Richardson
The emergence of azole-resistant Aspergillus fumigatus (ARAf) complicates the treatment of aspergillosis and can nearly double the mortality from invasive aspergillosis (IA). ARAf has been isolated from many different environmental sites and indoor environments and thus presents a significant risk for susceptible patients. Local surveillance of environmental ARAf can guide antifungal prescribing and improve patient outcomes. In this study, seventy-four soils samples collected from the surface of a variety of root vegetables from farm shops and private gardens covering a wide geographical area of the UK, were cultured to assess the presence of A. fumigatus, and the prevalence and nature of any resistance mechanisms. A high-throughput in-house antifungal susceptibility screening method was developed and validated using the EUCAST MIC reference method, E.DEF 9.3.1. A total of 146 isolates were recovered and analysed. Even though the study premise was that soil-covered root vegetables and other fresh produce could represent a conduit for ARAf exposure in vulnerable patients, no ARAf were found in the soil samples despite 55% of samples harbouring A. fumigatus. The sample type and screening method used could be suitable for more extensive monitoring of the soil to detect trends in the prevalence of ARAf.

2 January 2016 in AIDS
Verified
Journal Article
Closed access
CEChris Eades
Chris Eades
SHSophie A. Herbert
Sophie A. Herbert
SESimon G. Edwards
Simon G. Edwards
LWLaura J. Waters
Laura J. Waters
TPTabitha Peake
Tabitha Peake
EJEva Jungmann
Eva Jungmann
Among an inner London UK cohort of 147 adolescents transitioning from paediatric into adult care between 2007 and 2015, a new diagnosis of lymphoma was made in five patients; incidence rate = 0.425/100 person-years (95% confidence interval = 0.424–0.426). Previously described risk factors, including low nadir CD4+ cell count and ongoing HIV-1 viraemia, appeared to be important. These data suggest that careful surveillance and a low threshold for investigating relevant symptoms continue to be essential for such patients.

10 March 2025 in eJHaem
Verified
Journal Article
Open access
SASamir Agrawal
Samir Agrawal
ABAnjaneya Bapat
Anjaneya Bapat
CEChris Eades
Chris Eades
SGShreyans Gandhi
Shreyans Gandhi
Objective: To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML).Methods: Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms. The following filters were applied: published in the last 10 years and published in English.Results: The PubMed search yielded 54 results, of which 16 were deemed relevant for inclusion. Four additional references were identified through manual searches. The majority of publications focused on the incidence of IFD during treatment with targeted agents; the remainder focused on the efficacy of targeted treatments and reported IFD as an adverse event. Most publications were retrospective analyses. Prophylaxis use and agents differed across studies. In several studies, IFD incidence was above the 8% threshold identified for anti‐mould prophylaxis. Aspergillus was the most commonly reported pathogen, and most IFD cases occurred in the lungs.Conclusions: IFD is relatively common among patients with AML receiving targeted therapies, despite the use of prophylaxis. Prospective studies with detailed IFD reporting, together with large epidemiological studies, are required to better understand the risk factors for, and incidence and nature of IFD in this patient population.

24 April 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CEChris Eades
Chris Eades
ABAnjaneya Bapat
Anjaneya Bapat
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.